OR WAIT null SECS
Emmes, a full service, global clinical research organization(CRO), is launching its new center, Orphan Reach as a ‘rare CRO’.
The new rare disease center will incorporate Emmes’ reputation in public health research across the public sector and biopharmaceutical industry, with the knowledge of Orphan Reach, a UK-based specialty CRO acquired by Emmes in May 2021. The addition of Emmes’ biostatistics, data management, and global clinical trial execution capabilities will enable the center to function as a full, end to end services organization.
The expanded Orphan Reach forms a global specialty center dedicated to the advancement of rare disease research by providing specialized clinical trial design and execution capabilities.